Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.4 SEK | +2.11% | +1.04% | +25.49% |
08/05 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
17/04 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.49% | 60.36M | |
+8.57% | 72.5B | |
+13.69% | 9.11B | |
-11.75% | 5.07B | |
+59.61% | 5.01B | |
+2.62% | 3.85B | |
-17.54% | 2.46B | |
+21.27% | 2.44B | |
-27.82% | 2.26B | |
+25.13% | 2.27B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- US Court Confirms Validity of Orexo's Patents for Opioid Use Treatment Tablets